Table 1 Baseline characteristics

From: Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO)

Characteristic

ICT group (n = 52)

CRT group (n = 52)

Median age, years (range)

62.5 (45, 74)

63.0 (47, 74)

Sex, n (%)

Male

44 (84.6)

38 (73.1)

Female

8 (15.4)

14 (26.9)

ECOG performance status, n (%)

0

51 (98.1)

47 (90.4)

1

1 (1.9)

5 (9.6)

Tumor location, n (%)

Upper

11 (21.2)

12 (23.1)

Middle

25 (48.1)

30 (57.7)

Lower

16 (30.8)

10 (19.2)

Histologic grade, n (%)

Poorly-differentiated

1 (1.9)

4 (7.7)

Moderately-differentiated

36 (69.2)

35 (67.3)

Well-differentiated

14 (26.9)

10 (19.2)

Unknown

1 (1.9)

3 (5.8)

Clinical T stage, n (%)

T1

0

0

T2

4 (7.7)

6 (11.5)

T3

44 (84.6)

36 (69.2)

T4

4 (7.7)

10 (19.2)

Clinical N stage, n (%)

N0

5 (9.6)

7 (13.5)

N1

19 (36.5)

26 (50.0)

N2

26 (50.0)

19 (36.5)

N3

2 (3.8)

0

Clinical M stage, n (%)

M0

52 (100.0)

50 (96.2)

M1

0

2 (3.8)

Clinical stage, n (%)

I

0

0

II

5 (9.6)

11 (21.2)

III

41 (78.8)

31 (59.6)

IVA

6 (11.5)

8 (15.4)

IVB

0

2 (3.8)

PD-L1 CPS, n (%)

CPS < 5

30 (57.7)

25 (48.1)

CPS ≥ 5

4 (7.7)

5 (9.6)

CPS < 10

33 (63.5)

28 (53.8)

CPS ≥ 10

1 (1.9)

2 (3.8)

Unknown

18 (34.6)

22 (42.3)

  1. ICT neoadjuvant immunochemotherapy, CRT neoadjuvant chemoradiotherapy.
Back to article page